This website is intended for US Healthcare Professionals only.
Return to homepage
close

Access | Reimbursement Support | Connection

Stemline ARC® Connection

Connect eligible patients to comprehensive benefit and resource support throughout their treatment journey

A cancer diagnosis can be overwhelming. Stemline ARC offers ongoing support, answers to questions, and connection to resources to help your patients and their caregivers navigate the treatment journey. Support includes:

  • ARC Patient Advocates
  • Caregiving resources
  • Educational resources
  • Food and nutrition resources
  • Transportation support resources

ARC Patient Advocates

ARC Patient Advocates provide an overview of support services, confirm ELZONRIS coverage and financial assistance, share helpful resources, and are available to answer questions throughout your patients' treatment journey.*

ARC Patient Advocates provide support throughout your patients' treatment. Here are some of the questions ARC Patient Advocates can help answer for your patients:
  • How can I get financial assistance during my treatment?
  • How can I get help with transportation or meals?
  • How can I get coverage for ELZONRIS?
  • How do I handle getting reimbursed by insurance?
  • Where can I learn more about BPDCN?
  • Where can I find mental health support?
  • Where can I find patient, family, or caregiver support groups?
  • What kind of resources can I find online?

*ARC Patient Advocates are available to provide resource information and answer questions about financial assistance, insurance benefits, and coverage for ELZONRIS. This supplemental support is not intended to replace discussions between patients and their healthcare providers.

Caregiving resources

Caring for a loved one who is diagnosed with cancer can be daunting. Listed below are organizations that may be able to help educate and support your patients and the family members and friends who are caring for them. Visit these websites for helpful resources.

American Association of Retired Persons (AARP®)—A nonprofit, nonpartisan organization, with a membership of more than 38 million, that makes your patients’ goals and dreams possible, strengthens communities, and fights for the issues that matter most to families, such as healthcare, employment security, and retirement planning. www.aarp.org/caregiving

American Cancer Society Hope Lodge®—For cancer patients receiving treatment more than 40 miles away from home, as well as their caregivers, the Hope Lodge network provides a home away from home. www.cancer.org/treatment/support-programs-and-services/patient-lodging/hope-lodge

CancerCare®—Offers professional support services, information, and resources for caregivers and their loved ones free of cost. www.cancercare.org/tagged/caregiving

Cancer Support Community (CSC)—As the largest professionally led nonprofit network of cancer support worldwide, CSC annually provides more than $50 million in support services to patients and their loved ones at no cost. CSC consists of a global network of 190 locations, including CSC and Gilda's Club centers, healthcare partnerships, and satellite locations. 1-888-793-9355. www.cancersupportcommunity.org

Caregiver Action Network (CAN)—A nationwide nonprofit organization delivering free support services, education, and other resources to caregivers. www.caregiveraction.org

United States Department of Labor—For information on disability benefits, civil rights, community life, education, and employment. Find the US Social Security administration disability benefit eligibility screening tool, information, and assistance. www.dol.gov/agencies/odep/program-areas

Family Caregiver Alliance® (FCA)—The first US community-based nonprofit organization to deliver long-term care at home through its national-, state-, and local-level support services. www.caregiver.org

Health Insurance Marketplace—Enroll in a health plan, determine if you’ve had a life-changing event qualifying you for benefits, or just investigate ways to save money on healthcare expenses. 1-800-318-2596. www.healthcare.gov

Healthcare Hospitality Network—A nationwide network of nearly 200 nonprofit organizations providing lodging and support services to patients, families, and loved ones receiving medical treatment in locations far from their home communities. www.hhnetwork.org

Joe's House—A nonprofit organization helping cancer patients and their families find a place to stay when receiving treatment away from home. www.joeshouse.org

Centers for Medicare & Medicaid Services (CMS): Medicare—Offers outreach and education resources specifically for caregivers assisting a patient who is aged 65 years and older (or younger with certain disabilities) and who may be eligible for government-sponsored insurance. Topics include billing, navigating Medicare, support groups, and care options. www.cms.gov

National Alliance for Caregiving—Focuses on supporting caregivers through international advocacy, policy analysis, ongoing research, and public awareness of barriers facing caregivers. www.caregiving.org

Well Spouse® Association—Advocates for caregivers of a spouse or partner who is chronically ill and/or disabled, offering peer-to-peer support and education about the daily challenges of being a "well" spouse. 1-800-838-0879. www.wellspouse.org

Educational resources

Once a treatment plan has been established, many logistics must fall into place. Below are links to resources for educational support.

CancerCare®—Offers professional support services, information, and resources for caregivers and their loved ones free of cost. www.cancercare.org/tagged/caregiving

Cancer Financial Assistance Coalition (CFAC)—A support network committed to tackling the financial (and practical) barriers of cancer treatment. www.cancerfac.org

Cancer.Net®—Provides timely, comprehensive, oncologist-approved information from the American Society of Clinical Oncology, with support from the Conquer Cancer Foundation. www.cancer.net/navigating-cancer-care

Cancer Support Community (CSC)—As the largest professionally led nonprofit network of cancer support worldwide, CSC annually provides more than $50 million in support services to patients and their loved ones at no cost. CSC consists of a global network of 190 locations, including CSC and Gilda's Club centers, healthcare partnerships, and satellite locations. 1-888-793-9355. www.cancersupportcommunity.org

The Leukemia & Lymphoma Society®—Provides free blood cancer information and support to patients, families, survivors, and healthcare professionals. LLS also provides funding for groundbreaking research and advocates on the state and federal levels for policies that remove barriers to care for patients with blood cancer. www.lls.org

MyLifeLine®—Offers a free online communication platform where patients and caregivers can connect with each other and find key web resources to support the healing process. www.mylifeline.org

National Alliance for Caregiving—Focuses on supporting caregivers through international advocacy, policy analysis, ongoing research, and public awareness of barriers facing caregivers. www.caregiving.org

Food and nutrition resources

Explore helpful organizations for food delivery. Options will continue to be updated as they become available.

Meals on Wheels America—Specializes in delivering nutritious meals to high-risk seniors and other people with disabilities, and providing a daily dose of human contact along the way. www.mealsonwheelsamerica.org

Transportation support resources

Sometimes patients need help getting where they need to go. The organizations listed below may provide practical support with finding transportation when needed.

The Air Care Alliance (ACA)—A nonprofit public benefit 501(c)(3) organization incorporated in the state of California that facilitates charitable flights through cooperation between aviation associations and governmental agencies. www.aircarealliance.org

Air Charity Network—Coordinates free flights with volunteer pilots for your patients requiring long-distance doctor appointments, surgery, or treatment. 1-877-621-7177. www.aircharitynetwork.org

American Cancer Society® (ACS)—Provides your patients and their caregivers with 24/7 support throughout the treatment process, from free lodging and transportation to informative resources and emotional support. 1-800-227-2345. www.cancer.org

Angel Flight—A nonprofit charitable organization that arranges free medically related flight services to individuals in financial need and healthcare organizations. 1-918-749-8992. www.angelflight.com

Corporate Angel Network—A 501(c)(3) nonprofit organization dedicated to securing empty seats on corporate aircraft for cancer patients needing to access treatment centers throughout the United States. There is no cost for this service. (914) 328-1313. www.corpangelnetwork.org

Fisher House Foundation—Provides free housing at military bases and VA medical centers worldwide for family members of military or veterans to live comfortably while their loved one is hospitalized. 1-888-294-8560. www.fisherhouse.org

Patient AirLift Services—Arranges free air transportation for patients who need to travel for diagnosis, treatment, or follow-up. 1-888-818-1231. www.palservices.org

The above organizations provide support for cancer patients. This is not an exhaustive list. These organizations are independent from Stemline Therapeutics, Inc. ("Stemline"). Stemline has no financial interest in these organizations but may occasionally provide some financial support. All trademarks are property of their respective owners.

For questions or more information about Stemline ARC, call 1-833-4-STEMLINE (1-833-478-3654)
from 9:00 AM to 6:00 PM EST, Monday through Friday

BPDCN, blastic plasmacytoid dendritic cell neoplasm.

Enroll your patients in Stemline ARC®  today

INDICATION

  • ELZONRIS is a CD123-directed cytotoxin indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older

IMPORTANT SAFETY INFORMATION

Boxed WARNING: CAPILLARY LEAK SYNDROME

  • Capillary Leak Syndrome (CLS) which may be life-threatening or fatal, can occur in patients receiving ELZONRIS. Monitor for signs and symptoms of CLS and take actions as recommended.

WARNINGS AND PRECAUTIONS

Capillary Leak Syndrome

  • Capillary leak syndrome (CLS), including life-threatening and fatal cases, has been reported among patients treated with ELZONRIS. In patients receiving ELZONRIS in clinical trials, the overall incidence of CLS was 53% (65/122), including Grade 1 or 2 in 43% (52/122) of patients, Grade 3 in 7% (8/122) of patients, Grade 4 in 1% (1/122) of patients, and four fatalities (3%). The median time to onset was 4 days (range - 1 to 46 days), and all but 5 patients experienced an event in Cycle 1.
  • Before initiating therapy with ELZONRIS, ensure that the patient has adequate cardiac function and serum albumin is greater than or equal to 3.2 g/dL. During treatment with ELZONRIS, monitor serum albumin levels prior to the initiation of each dose of ELZONRIS and as indicated clinically thereafter, and assess patients for other signs or symptoms of CLS, including weight gain, new onset or worsening edema, including pulmonary edema, hypotension or hemodynamic instability.

Hypersensitivity Reactions

  • ELZONRIS can cause severe hypersensitivity reactions. In patients receiving ELZONRIS in clinical trials, hypersensitivity reactions were reported in 43% (53/122) of patients treated with ELZONRIS and were Grade ≥ 3 in 7% (9/122). Manifestations of hypersensitivity reported in ≥ 5% of patients include rash, pruritus, and stomatitis. Monitor patients for hypersensitivity reactions during treatment with ELZONRIS. Interrupt ELZONRIS infusion and provide supportive care as needed if a hypersensitivity reaction should occur.

Hepatotoxicity

  • Treatment with ELZONRIS was associated with elevations in liver enzymes. In patients receiving ELZONRIS in clinical trials, elevations in ALT occurred in 79% (96/122) and elevations in AST occurred in 76% (93/122). Grade 3 ALT elevations were reported in 26% (32/122) of patients. Grade 3 AST elevations were reported in 30% (36/122) and Grade 4 AST elevations were reported in 3% (4/122) of patients. Elevated liver enzymes occurred in the majority of patients in Cycle 1 and were reversible following dose interruption.
  • Monitor alanine aminotransferase (ALT) and aspartate aminotransferase (AST) prior to each infusion with ELZONRIS. Withhold ELZONRIS temporarily if the transaminases rise to greater than 5 times the upper limit of normal and resume treatment upon normalization or when resolved.

ADVERSE REACTIONS:

Most common adverse reactions (incidence ≥ 30%) are capillary leak syndrome, nausea, fatigue, pyrexia, peripheral edema, and weight increase. Most common laboratory abnormalities (incidence ≥ 50%) are decreases in albumin, platelets, hemoglobin, calcium, and sodium, and increases in glucose, ALT and AST.

Please see full Prescribing Information, including Boxed WARNING.


To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

IMPORTANT SAFETY INFORMATION

INDICATION

  • ELZONRIS is a CD123-directed cytotoxin indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older

IMPORTANT SAFETY INFORMATION

Boxed WARNING: CAPILLARY LEAK SYNDROME

  • Capillary Leak Syndrome (CLS) which may be life-threatening or fatal, can occur in patients receiving ELZONRIS. Monitor for signs and symptoms of CLS and take actions as recommended.

WARNINGS AND PRECAUTIONS

Capillary Leak Syndrome

  • Capillary leak syndrome (CLS), including life-threatening and fatal cases, has been reported among patients treated with ELZONRIS. In patients receiving ELZONRIS in clinical trials, the overall incidence of CLS was 53% (65/122), including Grade 1 or 2 in 43% (52/122) of patients, Grade 3 in 7% (8/122) of patients, Grade 4 in 1% (1/122) of patients, and four fatalities (3%). The median time to onset was 4 days (range - 1 to 46 days), and all but 5 patients experienced an event in Cycle 1.
  • Before initiating therapy with ELZONRIS, ensure that the patient has adequate cardiac function and serum albumin is greater than or equal to 3.2 g/dL. During treatment with ELZONRIS, monitor serum albumin levels prior to the initiation of each dose of ELZONRIS and as indicated clinically thereafter, and assess patients for other signs or symptoms of CLS, including weight gain, new onset or worsening edema, including pulmonary edema, hypotension or hemodynamic instability.

Hypersensitivity Reactions

  • ELZONRIS can cause severe hypersensitivity reactions. In patients receiving ELZONRIS in clinical trials, hypersensitivity reactions were reported in 43% (53/122) of patients treated with ELZONRIS and were Grade ≥ 3 in 7% (9/122). Manifestations of hypersensitivity reported in ≥ 5% of patients include rash, pruritus, and stomatitis. Monitor patients for hypersensitivity reactions during treatment with ELZONRIS. Interrupt ELZONRIS infusion and provide supportive care as needed if a hypersensitivity reaction should occur.

Hepatotoxicity

  • Treatment with ELZONRIS was associated with elevations in liver enzymes. In patients receiving ELZONRIS in clinical trials, elevations in ALT occurred in 79% (96/122) and elevations in AST occurred in 76% (93/122). Grade 3 ALT elevations were reported in 26% (32/122) of patients. Grade 3 AST elevations were reported in 30% (36/122) and Grade 4 AST elevations were reported in 3% (4/122) of patients. Elevated liver enzymes occurred in the majority of patients in Cycle 1 and were reversible following dose interruption.
  • Monitor alanine aminotransferase (ALT) and aspartate aminotransferase (AST) prior to each infusion with ELZONRIS. Withhold ELZONRIS temporarily if the transaminases rise to greater than 5 times the upper limit of normal and resume treatment upon normalization or when resolved.

ADVERSE REACTIONS:

Most common adverse reactions (incidence ≥ 30%) are capillary leak syndrome, nausea, fatigue, pyrexia, peripheral edema, and weight increase. Most common laboratory abnormalities (incidence ≥ 50%) are decreases in albumin, platelets, hemoglobin, calcium, and sodium, and increases in glucose, ALT and AST.

Please see full Prescribing Information, including Boxed WARNING.


To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.